- Home
- LCID vs ITCI Comparison
LCID vs ITCI Comparison
Compare LCID & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCID
- ITCI
- Stock Information
- Founded
- LCID 2007
- ITCI 2002
- Country
- LCID United States
- ITCI United States
- Employees
- LCID N/A
- ITCI N/A
- Industry
- LCID Auto Manufacturing
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- LCID Consumer Discretionary
- ITCI Health Care
- Exchange
- LCID Nasdaq
- ITCI Nasdaq
- Market Cap
- LCID 9.3B
- ITCI 8.0B
- IPO Year
- LCID N/A
- ITCI N/A
- Fundamental
- Price
- LCID $3.61
- ITCI $76.09
- Analyst Decision
- LCID Hold
- ITCI Strong Buy
- Analyst Count
- LCID 10
- ITCI 11
- Target Price
- LCID $3.55
- ITCI $97.00
- AVG Volume (30 Days)
- LCID 38.9M
- ITCI 445.2K
- Earning Date
- LCID 11-05-2024
- ITCI 10-31-2024
- Dividend Yield
- LCID N/A
- ITCI N/A
- EPS Growth
- LCID N/A
- ITCI N/A
- EPS
- LCID N/A
- ITCI N/A
- Revenue
- LCID $668,286,000.00
- ITCI $564,526,000.00
- Revenue This Year
- LCID $30.88
- ITCI $46.60
- Revenue Next Year
- LCID $108.70
- ITCI $37.06
- P/E Ratio
- LCID N/A
- ITCI N/A
- Revenue Growth
- LCID N/A
- ITCI 54.31
- 52 Week Low
- LCID $2.29
- ITCI $45.50
- 52 Week High
- LCID $5.70
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- LCID 48.40
- ITCI 50.28
- Support Level
- LCID $3.37
- ITCI $74.46
- Resistance Level
- LCID $3.96
- ITCI $76.98
- Average True Range (ATR)
- LCID 0.26
- ITCI 1.75
- MACD
- LCID -0.04
- ITCI 0.19
- Stochastic Oscillator
- LCID 26.23
- ITCI 54.78
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.